Hereditary Hyperferritinemia-cataract Syndrome

A Case Report of a Danish Family with a G32T Point Mutation of the FTL Gene

Cecilie Utke Rank,1 Jesper Petersen,2 Henrik Birgens3 and Ove Juul Nielsen1

1. Medical Doctor, Department of Haematology, Rigshospitalet University Hospital, Copenhagen, Denmark; 2. Molecular Biologist; 3. Medical Doctor, Department of Haematology, Herlev University Hospital, Herlev, Denmark

Abstract
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare autosomal dominant disorder associated with high plasma ferritin concentration without iron overload and early-onset bilateral cataract. The deregulation of ferritin production in HHCS is caused by mutations in the iron-responsive elements (IREs) of the ferritin L-subunit gene (FTL gene) – interfering with the high-affinity interaction between IREs and iron regulatory proteins (IRPs), disturbing the negative regulatory control of ferritin synthesis and resulting in excessive production of L-ferritin. We report a 44-year-old woman initially suspected of having hereditary haemochromatosis and later together with family members diagnosed with HHCS. Genetic analysis showed heterozygosity for a G32T point mutation (Paris 2 mutation) in the IRE located in the 5′ untranslated region (UTR) of the FTL gene. The differential diagnosis of hereditary haemochromatosis and HHCS together with the rarity and the versatile phenotype in HHCS obscures the diagnostic process, which emphasises the importance of the correct diagnosis of HHCS in order to prevent unnecessary phlebotomy.

Keywords
Hyperferritinemia-cataract syndrome, HHCS, Paris 2 mutation, hyperferritinemia, cataracts

Disclosure: Cecilie Utke Rank, Jesper Petersen, Henrik Birgens and Ove Juul Nielsen have no conflicts of interest to declare. No funding was received in the publication of this article.

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.

Compliance with Ethics Guidelines: All procedures were followed in accordance with the responsible committee on human experimentation and with the Helsinki Declaration of 1975 and subsequent revisions. Informed consent was received from the patient involved in this case study.

Received: 1 June 2015 Accepted: 10 July 2015 Citation: European Oncology & Haematology, 2015;11(2):147–9 DOI: http://doi.org/10.17925/EOH.2015.11.02.147

Correspondence: Cecilie Utke Rank, Department of Haematology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. E: CecilieUtkeRank@gmail.com

Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare autosomal dominant disorder associated with high plasma ferritin concentration without iron overload and early-onset bilateral cataract. HHCS was first described in 1995,1–3 and since then over 30 mutations, mainly point mutations and deletions, associated with HHCS have been reported.4–8

Isolated hyperferritinemia with plasma ferritin concentrations above 300 μg/l in men and 200 μg/l in women in an asymptomatic patient and in absence of inflammation and liver disease, most likely indicates increased iron stores and requires further investigation whether or not it is accompanied by iron overload – in order to differentiate between hereditary haemochromatosis (HH), haemosiderosis, ferroportin disease, aceruloplasminemia, ataxiasferremia and HHCS.1

Under normal physiological conditions, plasma ferritin reflects the amount of iron stored in tissue macrophages – apart from infectious, inflammatory, autoimmune and malignant diseases, where plasma ferritin also acts as an acute-phase reactant. Ferritin is composed of different subunits, L, H and G, which arrange to form different isoforms. The synthesis of these ferritin subunits is regulated by iron availability through an iron regulatory system. Iron-responsive elements (IREs) are one component of this system and are mRNA stem-loop structures located in the 5′ or in the 3′ untranslated regions (UTRs) of the genes involved in iron metabolism. IREs are crucial in regulating the cellular iron metabolism and coordinating the synthesis of various proteins involved in the iron metabolism, including transferrin receptor for cellular iron uptake, ferritin for intracellular iron storage and erythroid-specific δ-aminolevulinate synthase (δ-ALAS) for iron use for haemoglobin synthesis. The stem structure of the mRNA is interrupted by several bulges with a terminal loop that is essential for binding of cytoplasmic proteins called iron regulatory proteins (IRPs). IRPs are the other components of the iron regulatory system, which bind to IREs in response to iron deficiency, induce expression of transferrin receptors (increasing iron uptake) and repress the synthesis of ferritin and δ-ALAS (decreasing iron storage and iron use). The opposite occurs in conditions of iron excess.9–11

The deregulation of ferritin production in HHCS is caused by mutations in the IREs of the FTL gene – interfering with the high-affinity interaction between IREs and IRPs, leading to disrupted down-regulation/negative regulatory control by IRPs of L-ferritin mRNA translation and resulting...
Haematology

Table 1: Laboratory Findings

<table>
<thead>
<tr>
<th></th>
<th>P-ferritin/µg/l (12–300)</th>
<th>P-iron/µmol/l (9–34)</th>
<th>P-transferrin/µmol/l (24–41)</th>
<th>P-transferrin Saturation (0.2–0.5)</th>
<th>MCV/fl (82–98)</th>
<th>P-haemoglobin/mmol/l (7.3–9.5)</th>
<th>P-CRP/mg/l (&lt;10)</th>
<th>P-ALAT/U/l (10–45)</th>
<th>BM Biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proband</td>
<td>1,400</td>
<td>8</td>
<td>42.3</td>
<td>0.09</td>
<td>73</td>
<td>8.1</td>
<td>&lt;1</td>
<td>15</td>
<td>Decreased amount of stainable iron</td>
</tr>
<tr>
<td>Daughter of the proband</td>
<td>1,100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Son 1 of the proband</td>
<td>1,350</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Son 2 of the proband</td>
<td>1,150</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sister of the proband</td>
<td>1,490</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ALAT = alanine aminotransferase; BM = bone marrow; CRP = C-reactive protein; MCV = mean corpuscular volume; () = reference range. The darker area represents non-available data.

Figure 1: The G32T Point Mutation of the FTL Gene

RNA sequence secondary structure of the L-subunit iron-responsive element and the point mutation located in the 5' untranslated region of the FTL gene on chromosome 19q: G32T (the Paris 2 mutation). The arrow indicates the nucleotide substitution at position +32.
Hereditary Hyperferritinemia-cataract Syndrome

Discussion
When facing a high plasma ferritin concentration in an apparently healthy person, it is important – besides excluding HH in order to prevent organ damage caused by iron overload – to take HHCS into account, despite its rarity, because a mistaken diagnosis of HH could lead to rapid development of phlebotomy-iron chelation therapy-induced iron-deficient, microcytic anaemia and unnecessary liver biopsies. Thus, the differential diagnosis between HH and HHCS is essential and prevents unnecessary phlebotomy. In this case, plasma biochemical investigation of iron status, family genomic DNA-screening, and an ophthalmological examination are recommended. Craig et al.\(^5\) even propose cataract morphology to be pathognomonic for HHCS. Furthermore, it is important to consider spontaneous \textit{de novo} mutations in the \textit{FTL} gene causing non-hereditary hyperferritinemia cataract syndrome (non-H-HCS), which has been reported by Cao et al.\(^13\). With this in mind, HHCS should be taken into account even in sporadic cases of early-onset cataract formation.

Patients with HHCS present a versatile phenotype. A clinical variability among subjects sharing the same mutation has been demonstrated, in terms of plasma ferritin levels and time at onset and severity of cataract.\(^9,10,14\) Allerson, Cazzola and Rouault found a close correlation between decreases in the IRPs–IREs binding affinity and clinical severity.\(^5,8\) Ferrari et al.\(^2\) defined the hereditary hyperferritinemia-cataract syndrome as “a new dominant genetic disorder.” A prospective study demonstrated that the iron regulatory proteins contribute to phenotypic diversity, and that other genetic or environmental modifiers play a role in the severity of the disease. Herein, next-generation sequencing studies could be useful in a prospective setting.

It is likely that naturally occurring polymorphisms within mRNA regulatory proteins contribute to phenotypic diversity, and that other genetic or environmental modifiers play a role in the severity of the disease. A dominant mechanism for the severity of the disease is the mutation in the \textit{FTL} gene causing HHCS, which is characterized by increased plasma ferritin concentration and bilateral cataracts.\(^11\) The severity appears to be determined by the energetics of the IRPs–IREs binding interaction, and the latter varies among different mutations.\(^15\)

The severity of the disease is likely determined by the nature of the \textit{FTL} gene mutation.\(^1\) The severity appears to be determined by the energetics of the IRPs–IREs binding interaction, and the latter varies among different mutations.\(^15\)

Figure 2: Pedigree of the Family with HHCS

Circles denote female family members; squares denote male family members. White markers indicate affected heterozygous family members. The proband is indicated with a brown arrow. HHCS = hereditary hyperferritinemia-cataract syndrome.